The efficacy of olaparib in prostate cancer is primarily attributed to the presence of the BRCA2 gene within the NGS-HRR panel, while many other genes included in the above list do not render sensitivity to this drug [47,49]. This evidence concerns the gene BRCA2 and prostate cancer.